CHARLOTTE, N.C., Jan. 23, 2006 (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (OTCBB:CHTP), is scheduled to present at the Friedland Undervalued Equities Conference at 10:35 a.m. ET, Wednesday, January 25, at the Doubletree Metropolitan Hotel in New York City.
Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide an overview of the company and its current clinical development programs, including results from the recent Phase I clinical trial of its lead compound, CH-1504.
About the Friedland Investment Events' Undervalued Equities Conference
Friedland Investment Events LLC is the world's largest sponsor of financial and investment events, sponsoring over 280 events annually, in 28 U.S. cities and three European cities. These events include all-day conferences, breakfasts, luncheons and cocktail receptions. For more information or to register to attend the conference, please visit: http://www.friedlandevents.com.
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea develops technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Early clinical data suggests that Chelsea's lead product candidate, CH-1504, may support a safe and effective treatment for rheumatoid arthritis and may have further applications for psoriasis, certain cancers and other immunological disorders.
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks and costs of drug development, our history of losses and need to raise more money, regulatory approvals, intellectual property risks, our reliance on our lead drug candidate CH-1504, competition, market acceptance for our products if any are approved for marketing, reliance on key personnel including specifically Dr. Pedder, management of rapid growth, and the need to acquire or develop additional products.